Table 3.
Comparison between patients with a pathologic complete response (pCR) and a non-pCR.
| Parameters | pCR (n = 29) | Non-pCR (n = 234) | p value |
|---|---|---|---|
| Age (yrs), mean + SD | 41.4 ± 11.4 | 48.9 ± 9.5 | <0.001 |
| <50 | 23 (79.3) | 137 (58.5) | 0.031 |
| ≥50 | 6 (20.7) | 97 (41.5) | |
| Initial tumor size (cm) | 5.6 + 3.3 | 6.1 + 3.4 | 0.540 |
| <5 | 15 (51.7) | 121 (52.6) | 0.928 |
| ≥5 | 14 (48.3) | 109 (47.4) | |
| Surgery type | 0.005 | ||
| Mastectomy | 16 (55.2) | 184 (78.6) | |
| BCS | 13 (44.8) | 50 (21.4) | |
| ER | 0.006 | ||
| Negative | 17 (58.6) | 77 (32.9) | |
| Positive | 12 (41.1) | 157 (67.1) | |
| PgR | 0.004 | ||
| Negative | 21 (72.4) | 103 (44.0) | |
| Positive | 8 (27.6) | 131 (56.0) | |
| HER2 | |||
| Negative | 14 (48.3) | 154 (65.8) | 0.064 |
| Positive | 15 (51.7) | 80 (34.2) | |
| Subtype | 0.007 | ||
| Luminal A | 0 | 23 (9.8) | |
| Luminal B (HER-2 negative) | 4 (13.8) | 92 (39.3) | |
| Luminal B (HER-2 positive) | 8 (27.6) | 42 (17.9) | |
| HER-2 overexpression | 7 (24.1) | 38 (16.2) | |
| Triple-negative | 10 (34.5) | 39 (16.7) | |
| Any recurrence | |||
| No | 24 (82.8) | 151 (64.5) | 0.050 |
| Yes | 5 (17.2) | 83 (35.5) | |
| Locoregional recurrence | 0.037 | ||
| No | 29 (100.0) | 203 (86.8) | |
| Yes | 0 | 31 (13.2) |
Numbers in parentheses are percentages.
Abbreviations: ER: estrogen receptor; HER-2: human epidermal growth factor receptor 2; mean + SD: mean + standard deviation; pCR: pathological complete response; PgR: progesterone receptor.